That gap is a commercial architecture problem. The science is real. The translation to investor narrative, partner messaging, and buyer pathway has not been built, and commercial conversations stall because of it.
Built for life sciences and biotech CEOs and BD leaders at post-proof-of-concept companies. Applies to medtech VPs of Commercial, biopharma heads of corporate development, clinical-stage commercial leads, and similar operators translating science into commercial traction.
Investor narrative, partner-facing messaging, commercial buyer pathway, licensing readiness, 6-month sequencing. Written document your BD team operates from.
Start qualifying →Marketing strategy for biotech and life sciences companies translates scientific credibility into commercial credibility. The engagement covers investor narrative architecture, partner-facing messaging, commercial buyer pathway for hospitals and distributors, licensing conversation readiness, and 6-month commercial sequencing. Entry is the $5,000 Marketing Strategy Diagnostic delivered in 10 business days.
Life sciences buyers and investors do not all evaluate the same proof. The strategy has to translate scientific credibility into the language of risk, adoption, budget, and partnership value.
The narrative must connect science to market size, milestone logic, commercial pathway, and why now is the right capital moment.
Partner messaging needs capability, fit, defensibility, and a clear reason the relationship creates strategic leverage.
Commercial buyers need workflow impact, adoption path, clinical credibility, and implementation confidence.
The diagnostic turns scattered scientific and commercial claims into one narrative the company can use consistently.
A clinical-stage medtech company reduced investor deck cycle time by 60% after repositioning the commercial narrative. The science did not change. The translation did.
Every biotech and life sciences engagement we take on is some combination of these three. None of them are science problems. All of them are architecture problems.
Investors and partners read scientific proof differently than they read commercial readiness. A dataset that reads as definitive to a reviewer can read as early-stage to a distribution partner. The translation is structural, not cosmetic.
A novel diagnostic gets evaluated against legacy diagnostics because the buyer has no better frame. Your pricing, adoption assumptions, and switching story all get read against a reference class that does not fit. The work resets the frame before the conversation starts.
The scientific narrative speaks to one audience. The commercial narrative must speak to another. When the second narrative does not exist, BD and licensing conversations run in circles, and the deal memo never gets written.
The story a Series B lead or strategic investor needs to write the memo. Commercial inflection points mapped against the scientific milestones already in the deck.
The version of the story a distribution partner, strategic acquirer, or co-development counterparty reads and acts on. Rebuilt from a scientific source document for a BD audience.
Hospitals, health systems, labs, and distributors. The actual sequence of proof points, reference conversations, and pricing posture that a buyer needs to move from evaluation to purchase order.
Deal memo logic, counterparty qualification, and the commercial framing that separates early exploratory conversations from term-sheet conversations.
Biotech moves slower than SaaS. The sequencing is built around partner evaluation cycles, clinical publication cadence, and investor follow-on timing, not quarterly velocity.
A South San Francisco diagnostic company had completed two successful clinical studies and could not close a commercial partnership conversation. The diagnosis: the partner-facing narrative was written for scientists.
Eighteen weeks after repositioning for commercial buyers, two letters of intent from distribution partners. The science was always there. The commercial readability was not.
The strategist leading this work, whose broader practice is at stantscherenkow.com, has worked with technical founders on commercial translation for over a decade.
The engagement is structured around written output rather than retainer hours. You receive a strategy document your BD and commercial team operate from, independent of whether the relationship continues. The 10-business-day timeline and the fixed $5,000 scope exist to produce usable documents, not to anchor a retainer.
Biotech cycles are slower than SaaS cycles, and the work accounts for that. The sequencing is 6 months, not 90 days. Partner evaluation, clinical publication, and investor follow-on conversations each run on their own cadence, and the document reflects that reality rather than fighting it.
Investor narrative, partner messaging, buyer pathway, licensing framing, and 6-month sequencing delivered in 10 business days. Team owns it in perpetuity.
Deck, one-pager, and data room language reworked for BD audiences. The scientific source material is preserved. The audience-facing framing is not.
Outreach sequenced against publication and clinical milestone cadence. Early conversations convert into memo-stage conversations with counterparties who were previously unreachable.
Letters of intent, term sheets, or funded partnership conversations. Investor follow-on material ready for the next financing without a separate narrative rebuild.
The diagnostic is $5,000, delivered in 10 business days. These four questions calibrate the engagement to where your company actually is. All four are required.
Answers are written plainly so buyers, search engines, and answer systems can parse the engagement without guessing.
The engagement covers investor narrative architecture, partner-facing messaging, commercial buyer pathway design for hospitals, health systems, labs, and distributors, licensing conversation readiness, and a 6-month commercial sequencing roadmap. The deliverable is a written strategy document your team owns and executes. The focus is translating scientific credibility into commercial language without distorting the science.
The Strategy Diagnostic is delivered in 10 business days at $5,000 flat. The commercial sequencing the document recommends typically spans 6 months of execution. Biotech commercial cycles are slower than SaaS cycles, so the strategy timeline is built around partner evaluation, distribution negotiation, and investor follow-on conversations rather than quarterly velocity.
Scientific audiences read proof as mechanism, endpoint, and statistical power. Commercial audiences read proof as adoption risk, reimbursement path, switching cost, and revenue durability. The same dataset supports both readings but the translation is structural, not cosmetic. A clinical study that reads as definitive to a scientist can read as early-stage to a distribution partner if the commercial framing is missing.
Both. Pre-revenue biotech post proof-of-concept uses the work to build investor and partner narratives that hold up under commercial scrutiny. Revenue-stage life sciences companies use the work to scale from early traction into partnership, licensing, or health-system adoption. The engagement is built for companies past scientific validation and working on commercial translation.
Generic marketing work in life sciences often produces website copy and tradeshow collateral without touching the commercial architecture. The work here starts with the translation problem between scientific and commercial audiences, then produces investor narrative, partner messaging, buyer pathway, and sequencing. The deliverable is strategy your BD and commercial leads operate from, not assets your science team finds unrecognizable.
Marketing Strategy Diagnostic for biotech and life sciences. $5,000 flat. 10 business days. Investor narrative, partner messaging, buyer pathway, licensing readiness, 6-month sequencing.